ClinicalTrials.gg
TerminatedNCT05317013Updated Sep 23, 2022

CBD in Postmenopausal Women With Osteopenia

A Phase 1 interventional study of CBD and Placebo in Osteopenia, sponsored by Canopy Growth Corporation. Terminated at 1 site in United States. Open to female participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-09-23.

Sponsored by Canopy Growth Corporation · Phase 1, Interventional, and Supportive care

Why this study was terminated
Low enrollment

From the registry’s dates

  • Primary completion was Sep 2022, 4 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 217 studies in Bone Diseases, Metabolic with a site in United States — 16 open to participants now, 21 under way, 1 of them phase 3. Bone Diseases, Metabolic · United States.

Enrollment
165th of 171
2 · median 66
Started
2022
with 7 others
Phase 1
16 of 217
1 open now
Registered
201st of 217
by date

Among the 217 studies in Bone Diseases, Metabolic with a site in United States, this one is the 165th largest by enrollment of the 171 interventional ones that give a count, is one of 8 that started in 2022, is one of 16 in phase 1, and was the 201st registered.

Bone Diseases, Metabolic

662 studies on the registry are indexed under Bone Diseases, Metabolic; 94 are open to participants now.

Browse Bone Diseases, Metabolic studies →

Open to participants now

16 of the 217 studies in Bone Diseases, Metabolic with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.

This study: 50 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Bone Diseases, Metabolic with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, double-blind, placebo-controlled, repeated-dose study to assess the safety, tolerability, and preliminary effects of CHI-554 in postmenopausal women ages 50-80 years who have osteopenia.

03

Conditions studied

  • Osteopenia
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is a female aged 50-80 years, inclusive, at the time of screening.
  • Is , defined as > or = 12 months amenorrhoea.
  • Has osteopenia, defined as T score at lumbar spine or femoral neck or total femur of less than -1.0, but not less than or equal to -2.5, according to dual energy x-ray absorptiometry (DXA) completed at the Screening Visit or performed at NM Clinical Research \& Osteoporosis Center up to 6 months prior to the Screening Visit.
  • Has been on a stable dose of 500 mg calcium daily for at least 7 days prior to Visit 1.
  • Has a between 18 and 35 kg/m2 (inclusive).
  • Is judged by the Investigator to be in generally good health at screening based on participants' medical history.
  • Must be adequately informed of the nature and risks of the study and give written prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Has a history of epilepsy, hepatitis, or .
  • Current or history of use of one or more prohibited medications (as described in Section 8.2.1.1).
  • Changes in the use of a prescription, over-the-counter (OTC), systemic or topical drug(s), herbal supplement(s), or vitamin(s) for the 4 weeks prior to the Screening Visit.
  • Evidence of hepatic or renal impairment including (ALT) or aspartate aminotransferase (AST) >1.5× the (ULN), or >2× ULN.
  • Has any clinically significant condition or abnormal finding at screening that would, in the opinion of the Investigator, preclude study participation or interfere with the evaluation of the study IP.
  • Has a history of a known significant allergic condition, significant drug-related , or allergic reaction to any compound or chemical class related to cannabis, including phytocannabinoids and cannabinoid analogues, or utilized within the IP (e.g., coconut; coconut oil; medium-chain triglycerides).
  • Has taken grapefruit products and/or Seville oranges within the 7 days prior to Visit 1.
  • Positive urine dipstick results for THC at the Screening Visit.
  • Has a history or current diagnosis of a significant psychiatric disorder, including alcohol or substance use disorder, that would, in the opinion of the Investigator, affect the subject's ability to comply with the study requirements.
  • Has participated in any product or device study within 30 days prior to the Screening Visit, or is scheduled to participate in another investigational product or device study during the course of this study.
  • Demonstrates behavior indicating unreliability or inability to comply with the requirements of the protocol.
  • History of Osteoporosis diagnosis.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Group A - 100 mg CBD

    100 mg CBD per day

    Drug: CBD

  • Experimental
    Group B - 300 mg CBD

    300 mg CBD per day

    Drug: CBD

  • Placebo comparator
    Group C - Placebo

    Placebo

    Other: Placebo

Interventions

  • DrugCBD

    CBD

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability: Adverse Events/Serious Adverse Events

    Adverse Events/Serious Adverse Events

    Time frame: Week 4

  2. Safety and Tolerability: Adverse Events/Serious Adverse Events

    Adverse Events/Serious Adverse Events

    Time frame: Week 8

  3. Safety and Tolerability: Adverse Events/Serious Adverse Events

    Adverse Events/Serious Adverse Events

    Time frame: Week 12

  4. Safety and Tolerability: Alanine aminotransferase (ALT)

    Alanine aminotransferase

    Time frame: Week 4

  5. Safety and Tolerability: Alanine aminotransferase (ALT)

    Alanine aminotransferase

    Time frame: Week 12

  6. Safety and Tolerability: Aspartate aminotransferase (AST)

    Aspartate aminotransferase

    Time frame: Week 4

  7. Safety and Tolerability: Aspartate aminotransferase (AST)

    Aspartate aminotransferase

    Time frame: Week 12

  8. Safety and Tolerability: Total bilirubin

    Total bilirubin

    Time frame: Week 4

  9. Safety and Tolerability: Total bilirubin

    Total bilirubin

    Time frame: Week 12

  10. Safety and Tolerability: Blood pressure

    Blood pressure - Systolic and diastolic blood pressure

    Time frame: Week 4

  11. Safety and Tolerability: Blood pressure

    Blood pressure - Systolic and diastolic blood pressure

    Time frame: Week 12

  12. Safety and Tolerability: Heart rate

    Heart rate

    Time frame: Week 4

  13. Safety and Tolerability: Heart rate

    Heart rate

    Time frame: Week 12

Secondary outcomes

  1. Serum CTx

    Serum CTx

    Time frame: Week 4

  2. Serum CTx

    Serum CTx

    Time frame: Week 12

  3. Serum P1NP

    Serum P1NP

    Time frame: Week 4

  4. Serum P1NP

    Serum P1NP

    Time frame: Week 12

  5. Serum Osteocalcin

    Serum Osteocalcin

    Time frame: Week 4

  6. Serum Osteocalcin

    Serum Osteocalcin

    Time frame: Week 12

  7. Serum Bone-specific alkaline phosphatase

    Serum Bone-specific alkaline phosphatase

    Time frame: Week 4

  8. Serum Bone-specific alkaline phosphatase

    Serum Bone-specific alkaline phosphatase

    Time frame: Week 12

07

Study locations

1 site
  • NM Clinical Research & Osteoporosis Center, Inc.
    Albuquerque, New Mexico 87106, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Sep 2022, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2022
First posted
Apr 7, 2022
StartActual
May 1, 2022
Primary completionActual
Sep 22, 2022
CompletionActual
Sep 22, 2022
Last update
Sep 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05317013
Lead sponsor
Canopy Growth Corporation
Collaborators
NM Clinical Research & Osteoporosis Center, Inc.
Responsible party
Sponsor
First posted
Apr 7, 2022
Start date
May 1, 2022
Primary completion
Sep 22, 2022
Completion
Sep 22, 2022
Last update
Sep 23, 2022

Study contacts

Lance Rudolph, MD
principal investigator · NM Clinical Research & Osteoporosis Center, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion